Home › Kidney Cancer › Illinois
Kidney Cancer clinical trials in Illinois
7 studies for Kidney Cancer are looking for participants at sites in Illinois.
Cities in Illinois
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Research Site, Zion
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07011719Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Memorial Hospital, Shiloh
- Siteman Cancer Center - Shiloh, Shiloh
- City Of Hope - Chicago, Zion
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07227415Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- NEO-811 Chicago Site, Zion
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT07300241Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Chicago
- Xencor Investigative Site, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05433142Integrated Cancer Repository for Cancer Research
- Rush-Copley Cancer Care Center, Aurora
- Rush-Copley Healthcare Center, Yorkville
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors
- Loyola University Medical Center, Edward Hines VA Hospital, Chicago
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 6, 2022 · NCT05363657From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.